4.20Open4.20Pre Close0 Volume0 Open Interest23.00Strike Price0.00Turnover658.16%IV43.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry4.20Extrinsic Value100Contract SizeAmericanOptions Type0.5420Delta0.0284Gamma4.50Leverage Ratio-0.6418Theta0.0008Rho2.44Eff Leverage0.0084Vega
Rigel Pharmaceuticals Stock Discussion
whoa! some Dip
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
Let's Get 30.+
No comment yet